Sélectionner la langue
Mucin-1
Mucin-1 Informations sur la molécule
| Nom anglais | Mucin-1 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 28 | Alias de la cible | PEM，Medullary Cystic Kidney Disease 1 (Autosomal Dominant)，Tumor Associated Epithelial Mucin，CD227 Antigen，H23 Antigen，MUC-1/SEC，ADMCKD1，Cancer antigen 15-3，Tumor-associated mucin，MUC1-alpha，MUC1-beta，MUC-1/X，MUC1/ZD，Mucin-1，ADMCKD，MCKD1，MAM6，MCKD，MCD，Polymorphic epithelial mucin，PUM，MUC1-NT，Episialin，CD227，MUC1-CT，MUC1，Mucin 1， Cell Surface Associated，Tumor-Associated Epithelial Membrane Antigen，Peanut-Reactive Urinary Mucin，Carcinoma-Associated Mucin，Krebs Von Den Lungen-6，CA 15-3，H23AG，MUC-1，KL-6，PEMT，EMA，Breast carcinoma-associated antigen DF3，Mucin 1， Transmembrane |
| Phase de R&D la plus avancée | Phase 2 Clinical | ||
| Nom anglais | Mucin-1 |
| Alias de la cible | PEM，Medullary Cystic Kidney Disease 1 (Autosomal Dominant)，Tumor Associated Epithelial Mucin，CD227 Antigen，H23 Antigen，MUC-1/SEC，ADMCKD1，Cancer antigen 15-3，Tumor-associated mucin，MUC1-alpha，MUC1-beta，MUC-1/X，MUC1/ZD，Mucin-1，ADMCKD，MCKD1，MAM6，MCKD，MCD，Polymorphic epithelial mucin，PUM，MUC1-NT，Episialin，CD227，MUC1-CT，MUC1，Mucin 1， Cell Surface Associated，Tumor-Associated Epithelial Membrane Antigen，Peanut-Reactive Urinary Mucin，Carcinoma-Associated Mucin，Krebs Von Den Lungen-6，CA 15-3，H23AG，MUC-1，KL-6，PEMT，EMA，Breast carcinoma-associated antigen DF3，Mucin 1， Transmembrane |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 28 |
| Phase de R&D la plus avancée | Phase 2 Clinical |
Mucin-1 Liste de produits
- Attribut
Protein (19)Antibody (1)Kits (1)
- Bibliothèque de produits
En ligne (21)
- Espèces
Human (13)Cynomolgus (5)Mouse (3)
- Étiquette
Fc Tag (7)Llama IgG Fc Tag (1)His Tag (6)His Tag & Avi Tag (3)Mouse IgG Fc Tag (2)- (2)
- Marqueur
Unconjugated (16)Biotin-labeled (3)APC Labeled (1)- (1)
Ajouter au panier
Quantité totale21
- 1
- 2
- 3
Mucin-1Contexte de la molécule
Membrane mucins have several functions in epithelial cells including cytoprotection, extravasation during metastases, maintenance of luminal structure, and signal transduction. MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites. Interacts via its C-terminus with PDZK1 and this interaction appears important for proper localization. Probably plays a role in maintaining homeostasis on mucosal surfaces.
Mucin-1Alias de la molécule
Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1,SEC,MUC-1,X,MUC1,ZD,PEM,PEMT,PUM,CA15-3,Episialin
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms | Details |
| PD-1 Knockout Anti-MUC1 CAR-T Cells (Guangzhou Anjie Biomedical) | AJMUC1 | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Prostatic Neoplasms | Details |
| Anti-MUC1 monoclonal antibody (OncoQuest) | AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 | Phase 2 Clinical | Altarex | Pancreatic Neoplasms | Details |
| GO-2032c | GO-203-2C | Phase 2 Clinical | Dana-Farber Cancer Institute, Genus Oncology Llc | Leukemia, Myeloid, Acute; Multiple Myeloma; Solid tumours | Details |
| MUC1-Poly-ICLC | MUC1-poly-ICLC | Phase 2 Clinical | University Of Pittsburgh | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma | Details |
| EB-DT-CAR-NK | EB-DT-CAR-NK | Phase 2 Clinical | Beijing Biotech | Breast Neoplasms; Triple Negative Breast Neoplasms | Details |
| EB-DNK102 | EB-DNK102 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | Details |
| EB-DNK101 | EB-DNK101 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | Details |
| DS-3939 | DS-3939; DS-3939a; GT-00A | Phase 2 Clinical | Daiichi Sankyo Inc | Solid tumours | Details |
| BM7PE | Phase 2 Clinical | Oslo University Hospital | Colorectal Neoplasms | Details | |
| Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology, The First Affiliated Hospital Of Guangdong Pharmaceutical University, University of Sydney | Carcinoma, Non-Small-Cell Lung | Details | |
| huMNC2-CAR44 | huMNC2-CAR44 | Phase 1 Clinical | Minerva Biotechnologies Co | Metastatic breast cancer | Details |
| ICTCAR-052 | ICTCAR-052 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Breast Neoplasms; Lung Neoplasms; Pancreatic Neoplasms | Details |
| recombinant adenovirus vector vaccine targeting MUC1 (MicroVax) | Phase 1 Clinical | Microvax Llc | Neoplasms | Details | |
| P-MUC1C-ALLO1 | P-MUC1C-ALLO1; P-MUC1C-101 | Phase 1 Clinical | Poseida Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| NEOK-002 | ABL209; ABL-209; NEOK002; NEOK-002 | Phase 1 Clinical | Abl Bio Inc, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Neoplasms; Solid tumours | Details |
| M-0324 | M-0324; M0324 | Phase 1 Clinical | Merck KGaA, Darmstadt, Germany | Neoplasms; Solid tumours | Details |
| YB-01(Yuanben (Zhuhai Hengqin) Biotech) | YB01; YB-01 | Phase 1 Clinical | Yuanben (Zhuhai Hengqin) Biotechnology Co Ltd | Arthritis, Rheumatoid; Solid tumours | Details |
| SBO-154 | SBO-154 | Phase 1 Clinical | Sun Pharmaceutical Advanced Research Co Ltd | Breast Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| ICTCAR-053 | ICTCAR-053 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
| BGB-B3227 | BGB-B3227 | Phase 1 Clinical | BeOne Medicines (Beijing) Co Ltd | Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| MUC1-peptide-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| MUC1-gene-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| DM-002 | DM-002; DM002 (Danma) | Phase 1 Clinical | Danma (Suzhou) Biomedical Technology Co Ltd | Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
| Recombinant HSP-MUC1 fusion protein (Newsummit) | Phase 1 Clinical | Shanghai Xinshengyuan Biological Medicine Co Ltd | Breast Neoplasms | Details | |
| DXC-005 | DXC-005 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Solid tumours | Details |
| ICTCAR-046 | ICTCAR-046 | Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :